The International Myeloma Foundation Says Pomalidomide, an Important New Drug for Patients, Has Been Submitted for FDA Approval | Investor Stemcell.
NORTH HOLLYWOOD, Calif., Apr 27, 2012 (BUSINESS WIRE) — The International Myeloma Foundation (IMF) — the oldest and largest foundation dedicated to improving the life and care of myeloma patients — said a new drug for multiple myeloma has been submitted to the US Food and Drug Administration for approval.
The drug, called pomalidomide, developed by CELGENE, would be used for patients with multiple myeloma who no longer respond to other therapies and would join the important, yet limited, number of drugs approved to fight this cancer. No new drugs have been approved for multiple myeloma in nearly six years. Read More
FDA Approves Pazopanib for Advanced Soft Tissue Sarcoma
It inhibits vascular endothelial growth-factor receptors (VEGFR-1, 2, and
3), platelet-derived growth-factor receptors (PDGFR-α and β), fibroblast
growth-factor receptors (FGFR1 and 3), stem cell factor receptors (c-Kit), interleukin-2-inducible T-cell …